BAP31, a promising target for the immunotherapy of malignant melanomas

Shuzhi Yu, Fuli Wang, Li Fan, Yuying Wei, Haitao Li, Yuanjie Sun, Angang Yang, Boquan Jin, Chaojun Song, Kun YangJournal of Experimental & Clinical Cancer Research 2015 · DOI

TL;DR

Researchers have identified BAP31, a protein overexpressed in malignant melanomas (MMs), as a promising new target for cancer immunotherapy. They developed and tested DNA vaccines encoding BAP31 in mice, demonstrating that these vaccines can effectively stimulate an immune response and suppress tumor growth, paving the way for potential human clinical trials.

What Problem Does This Paper Address?

Malignant melanoma (MM) is a particularly aggressive form of skin cancer with a high mortality rate, especially when diagnosed at later stages. Despite advances in treatment, the prognosis for disseminated MM remains poor. A key strategy in combating cancer is immunotherapy, which leverages the body's own immune system to fight the disease. This approach relies on identifying specific "tumor antigens" – molecules that are uniquely or highly expressed on cancer cells but not on normal cells. These antigens can then be targeted by the immune system. While many tumor antigens have been identified, the search for novel, highly effective targets for MM immunotherapy is ongoing. This paper addresses the need for new therapeutic targets by investigating BAP31, a protein known to be involved in cellular processes and apoptosis, and exploring its potential as a target for MM immunotherapy.

Methods

The study employed a multi-pronged approach:

  • Immunohistochemistry (IHC): This technique was used to visualize and quantify the protein expression levels of BAP31 in both human melanoma tissues and normal human tissues, as well as in mouse melanoma cells and normal mouse tissues. This allowed the researchers to determine if BAP31 is indeed overexpressed in melanoma.
  • DNA Vaccine Construction: Novel DNA vaccines were engineered. Specifically, they created a DNA vaccine encoding mouse BAP31 (mBAP31). To enhance the immune response, they also developed a "chimera" vaccine where mBAP31 was fused with the lysosome-associated membrane protein (LAMP). LAMP is known to help deliver antigens to the immune system's antigen-presenting cells.
  • Animal Immunization and Immune Response Evaluation: Female C57BL/6 mice were immunized with the constructed DNA vaccines (p-mBAP31, p-LAMP/mBAP31) or a control (PBS). The immune response was assessed using:
  • ELISPOT Assay: This assay measures the frequency of immune cells (splenocytes) that produce interferon-gamma (IFN-γ), a key cytokine indicating an active T-cell response, in response to BAP31-specific peptides.
  • Cytotoxicity Assay (LDH Release): This assay quantifies the ability of cytotoxic T lymphocytes (CTLs) from vaccinated mice to kill BAP31-expressing target cells.
  • Therapeutic Anti-tumor Model: Mice were first implanted with B16 melanoma cells, and then treated with the DNA vaccines. Tumor growth was monitored over time to assess the therapeutic efficacy of the vaccines.
  • Western Blotting: Used to confirm the expression of mBAP31 in cell lines and to verify the effectiveness of siRNA in reducing mBAP31 expression.
  • RNA interference (RNAi): siRNA was used to specifically knock down mBAP31 expression in B16 melanoma cells to study the effect of BAP31 depletion.

Datasets

The study utilized the following:

  • Human Melanoma Tissues: 141 human malignant melanoma (MM) tissue samples were analyzed for BAP31 protein expression.
  • Normal Human Tissues: Various normal human tissues were analyzed by IHC to establish baseline BAP31 expression.
  • Normal Mouse Tissues: Various normal mouse tissues were analyzed by IHC to establish baseline mBAP31 expression.
  • Cell Lines:
    • 293T cells: Used for transient transfection to assess protein expression from DNA vaccines.
  • Mouse colon carcinoma cell line CT26 (H-2d): Used as a target cell in cytotoxicity assays.
  • Mouse melanoma cell line B16 (H-2b): Used as a target cell in cytotoxicity assays and in the therapeutic anti-tumor model.
  • 2E8 cells: A clonal cell line derived from B16 cells with significantly reduced mBAP31 expression, used as a control in cytotoxicity assays.

No new benchmarks were introduced; the study focused on evaluating BAP31 as a target using established experimental models.

Key Insights and Ideas

  • BAP31 as a Novel MM Antigen: The most significant insight is the identification of BAP31 as a protein that is dramatically upregulated in human MM tissues compared to normal tissues. This strongly suggests it's a viable target for immune attack.
  • Specificity of BAP31 Expression: The study found that while BAP31 RNA transcripts are ubiquitous, protein expression is largely restricted to a minority of cells in normal tissues. This specificity is crucial for an effective cancer vaccine, minimizing off-target effects on healthy cells.
  • LAMP Enhancement of Immune Response: Fusing BAP31 with LAMP significantly boosted the cellular immune response (IFN-γ production) and CTL cytotoxicity compared to the BAP31 vaccine alone. This highlights the utility of LAMP as an adjuvant for DNA vaccines.
  • Therapeutic Efficacy in Established Tumors: The LAMP-mBAP31 vaccine demonstrated potent anti-tumor activity even when administered after tumors had already established, suggesting its potential for treating existing melanomas.
  • Safety Profile: Vaccinated mice showed no signs of autoimmune disorders, indicating a favorable safety profile for this vaccine approach.

Key Results

  • High BAP31 Expression in MMs: 86.5% (122 out of 141) of human MM tissues showed positive BAP31 protein expression, with intense staining in the cytoplasm of tumor cells.
  • Limited BAP31 Expression in Normal Tissues: BAP31 protein expression was found in only a minority of cells in some normal human tissues (lung, colon, rectum) and was negative in others (skin, ovary, breast, cervix, esophagus). In mice, mBAP31 protein was predominantly found in splenocytes, with minimal expression in other organs.
  • Robust Cellular Immunity: Mice vaccinated with p-LAMP/mBAP31 DNA vaccine showed significantly higher IFN-γ production by splenocytes compared to those vaccinated with p-mBAP31 alone or PBS.
  • Effective Cytotoxicity: CTLs from vaccinated mice could effectively kill B16 melanoma cells and BAP31-pulsed target cells. The LAMP fusion further enhanced this cytotoxic activity.
  • Tumor Growth Suppression: Vaccination with both p-mBAP31 and p-LAMP/mBAP31 significantly inhibited B16 melanoma tumor growth in mice. The p-LAMP/mBAP31 vaccine showed superior anti-tumor activity.
  • Increased CD8+ T Cell Infiltration: Treatment with the p-LAMP/mBAP31 vaccine led to increased infiltration of CD8+ T cells into tumor tissues.

Limitations and Future Work

  • Discrepancy between mRNA and Protein Expression: The authors note a discrepancy between the ubiquitous expression of BAP31 RNA transcripts and the more restricted protein expression in normal tissues. The mechanisms underlying this difference warrant further investigation.
  • Human Clinical Trials: The study's findings are based on mouse models. The authors explicitly state that these are the first data supporting a BAP31 vaccine for human MMs and that hBAP31 DNA vaccine warrants investigation in human clinical trials.
  • Mechanism of BAP31's Role in Tumorigenesis: While preliminary work suggested BAP31 depletion negatively impacts tumor cell proliferation and may facilitate resistance to apoptosis, further experiments are needed to fully elucidate BAP31's role in tumorigenesis.
  • Further Preclinical Studies: The paper mentions that preclinical trials for the LAMP-mBAP31 chimera DNA vaccine are ongoing, suggesting further optimization and validation steps before human trials.

Summary updated

Abstract

These are the first data supporting a vaccine targeting BAP31 that is capable of inducing effective immunity against BAP31-expressing MMs and will be applicable to human MMs and hBAP31 DNA vaccine warrants investigation in human clinical trials.
BibTeX
@article{yu2015bap,
  author = {Shuzhi Yu and Fuli Wang and Li Fan and Yuying Wei and Haitao Li and Yuanjie Sun and Angang Yang and Boquan Jin and Chaojun Song and Kun Yang},
  title = {{BAP31, a promising target for the immunotherapy of malignant melanomas}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2015},
  doi = {10.1186/s13046-015-0153-6},
}
Figure